However, DPP4-inhibitors might have adverse effects on diabetic retinopathy by promoting vascular leakage because DPP4-inhibitors increase active SDF-1α concentration which would activate the SDF-1α/CXCR4/Src pathway. This evidence concerns the gene CXCL12 and diabetic retinopathy.